Question explored with the scientific record
Conversation so far
- 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
- 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
- 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear? + a private exchange
- 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions? + a private exchange
- 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test? + a private exchange
- 6 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity? + a private exchange
- 7 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established? + a private exchange
- 8 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control? + a private exchange
- 9 Can problems from stopping digoxin develop gradually over several months rather than immediately? + a private exchange
- 10 What findings would help determine whether worsening edema, fatigue and shortness of breath after stopping digoxin were caused by the withdrawal rather than the underlying heart disease? + a private exchange
- 11 What evidence would justify abruptly stopping digoxin in an 88-year-old who had taken it for 30 years without first obtaining an ECG or echocardiogram? + a private exchange
- 12 If digoxin toxicity is suspected, what clinical findings should be documented before concluding that the drug should be stopped? + a private exchange
- 13 If an elderly patient refuses an ECG, does that make stopping long-term digoxin safer, or does it increase uncertainty about stopping it? + a private exchange
- 14 If digoxin had been controlling previously unrecognized heart failure, what could happen after it is stopped while metoprolol is continued? + a private exchange
- 15 Can stopping digoxin unmask previously compensated heart failure even if the patient does not deteriorate immediately? + a private exchange
- 16 What evidence would make it unlikely that stopping digoxin contributed to a patient's later heart failure? + a private exchange
- 17 If digoxin toxicity is suspected, should treatment decisions be based on an early post-dose level that the laboratory itself says is non-interpretable, or should another properly timed level and clinical assessment be obtained? + a private exchange
- 18 How quickly should serum digoxin fall after the drug is completely stopped in an elderly patient with normal kidney function? + a private exchange
- 19 If a patient has taken digoxin successfully for 30 years, what evidence would be needed to determine whether the drug is still providing a clinical benefit before withdrawing it? + a private exchange
- 20 If severe aortic stenosis is suspected but the echocardiogram is still pending, does that change the risks or precautions involved in stopping long-term digoxin?
Answered on this page ↓
If severe aortic stenosis is suspected but the echocardiogram is still pending, does that change the risks or precautions involved in stopping long-term digoxin?
Bottom line: suspected severe aortic stenosis with a pending echo does not change the core risk of stopping digoxin, but it changes what you must watch for and how fast you must act.
Digoxin in long-term use is not a disease-modifying drug. It is a symptom mask. It slows the heart and strengthens the squeeze in a failing ventricle. If you stop it, the risk is not a sudden electrical event. The risk is that the heart that was barely compensated loses its crutch and decompensates over days to weeks. That risk exists whether the echo is pending or not.
Severe aortic stenosis changes the picture because the ventricle is not just weak, it is pressure-overloaded. The valve is a fixed obstruction. The heart cannot compensate by increasing output, because the door will not open wider. If digoxin was holding that system together, stopping it can unmask failure faster and harder than in a patient with a normal valve. The pending echo does not change the decision to stop. It changes the monitoring. You do not wait for the echo to decide whether to taper. You taper, and you watch for the signs of forward failure: shortness of breath on less effort, waking gasping at night, swelling in the ankles, a drop in blood pressure, a rise in heart rate.
The precaution that matters most is not about digoxin itself. It is about the aortic stenosis. If the stenosis is truly severe, the definitive treatment is valve replacement, not digoxin. Digoxin is a bridge, not a destination. Stopping it while the echo is pending is not reckless. It is actually the right move if the drug is no longer needed or if there is a reason to question it, like toxicity, bradycardia, or confusion. But you must be honest about what you do not know. You do not know the valve area, the gradient, or the ejection fraction. You are flying without instruments.
The evidence on digoxin withdrawal is thin. The DIG trial from the 1990s showed that stopping digoxin in stable heart failure increased the risk of worsening heart failure and hospitalizations compared to continuing it. That was a randomized trial, but it was in patients with reduced ejection fraction, not necessarily with aortic stenosis. The withdrawal studies in the meta-analysis you mention are mostly small, short, and industry-funded. They compare stopping one drug against continuing it, but they rarely include patients with significant valve disease. So the honest answer is: the data does not tell you exactly what happens in your specific case. The mechanism tells you the risk is real, and the severity of the stenosis tells you the margin for error is smaller.
One more thing. If the echo comes back showing severe aortic stenosis, the conversation changes from digoxin to the valve. Digoxin becomes almost irrelevant. The question becomes whether you are a candidate for surgery or transcatheter valve replacement, and how fast that needs to happen. Stopping digoxin in that context is not the danger. The danger is the valve itself. Do not let the pending echo distract you from the fact that the real decision is about the obstruction, not the medication.
Sources used 19
-
Can Medications be Safely Withdrawn in Patients With Stable Chronic Heart Failure? Systematic Review and Meta-analysis
This systematic review and meta-analysis investigates the safety and outcomes of medication withdrawal in patients with stable chronic heart failure, revealing that discontinuation of RAAS inhibitors and beta-blockers is discouraged due to increased hospitalizations without mort…
DOI: 10.1016/j.cardfail.2014.04.013 -
A β-blocker, not magnesium, is effective prophylaxis for atrial tachyarrhythmias after coronary artery bypass graft surgery
This study evaluates the efficacy of magnesium versus propranolol in preventing postoperative atrial tachyarrhythmias after coronary artery bypass graft surgery, finding that propranolol significantly reduces incidence while magnesium does not provide any benefit.
DOI: 10.1053/jcan.2001.21959 -
The use of digitalis in heart failure
A comprehensive review of digitalis/digoxin in heart failure, detailing pharmacology, hemodynamic and neurohormonal effects, and a synthesis of randomized and observational studies showing symptomatic/hemodynamic benefits and reduced hospitalizations, but with inconsistent morta…
DOI: 10.1016/s0146-2806(96)80001-6 -
A rare case of pediatric intoxication: Bufotoxin bradycardia
An 8-year-old with bufotoxin exposure from toad eggs developed third-degree AV block and bradycardia and was successfully treated with digoxin-specific Fab antibodies, highlighting the importance of prompt antidotal therapy in rare pediatric bufotoxin intoxication.
DOI: 10.52768/2766-7820/1496 -
DRUG INDUCED BRADYCARDIA
Most patients experienced persistent bradycardia after stopping rate-slowing drugs, suggesting unmasked latent conduction system disease rather than true drug-induced bradycardia.
DOI: 10.29309/tpmj/2018.25.06.280 -
Echocardiographic left ventricular wall thickness: A poor predictor of the severity of aortic valve stenosis
Echocardiographic left ventricular wall thickness is not a reliable predictor of the severity of aortic stenosis, as defined by Gorlin valve area.
DOI: 10.1002/clc.4960140310 -
ROLE OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY IN THE DIAGNOSIS OF PARADOXICAL LOW FLOW, LOW GRADIENT SEVERE AORTIC STENOSIS DESPITE PRESERVED EJECTION FRACTION
This study investigates the prevalence of true paradoxical low flow, low gradient severe aortic stenosis (AS) using transesophageal echocardiography (TEE) measurements of left ventricular outflow tract (LVOT) diameter, finding that the prevalence is low (<10%) when reclassifying…
DOI: 10.1016/s0735-1097(14)62016-7 -
Impact of Classic and Paradoxical Low Flow on Survival After Aortic Valve Replacement for Severe Aortic Stenosis
This study compares the outcomes of patients with low ejection fraction (LEF), paradoxical low flow (PLF), and normal flow (NF) after aortic valve replacement (AVR) for severe aortic stenosis, revealing that both LEF and PLF are associated with higher operative risks and mortali…
DOI: 10.1016/j.jacc.2014.11.047 -
Impact of Three‐Dimensional Imaging and Pressure Recovery on Echocardiographic Evaluation of Severe Aortic Stenosis: A Pilot Study
This pilot study evaluates the impact of three-dimensional echocardiography and pressure recovery correction on the echocardiographic assessment of severe aortic stenosis, revealing that 3D imaging significantly improves accuracy in determining left ventricular outflow tract and…
DOI: 10.1111/echo.12509 -
Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Standard Care Among Inoperable Patients With Severe Aortic Stenosis
The PARTNER Cohort B trial evaluates the cost-effectiveness of transcatheter aortic valve replacement (TAVR) versus standard nonsurgical therapy in inoperable patients with severe aortic stenosis, finding longer life expectancy with an incremental cost per life-year gained aroun…
DOI: 10.1161/CIRCULATIONAHA.111.054072 -
Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis
This study investigates the prognostic impact of inappropriately high left ventricular mass (iLVM) in 218 patients with asymptomatic severe aortic stenosis, finding that iLVM is associated with a significantly higher rate of adverse cardiovascular events compared to appropriate …
DOI: 10.1136/hrt.2010.192997 -
The use of sublingual nitroglycerin in patients with severe aortic stenosis before cardiac CT - prospective suty
Prospective single-center study evaluating the safety and hemodynamic impact of 0.5 mg sublingual nitroglycerin before cardiac CT in patients with severe aortic stenosis undergoing pre-TAVI planning, finding a larger drop in systolic blood pressure in the SLN group but no major …
DOI: 10.1093/ehjci/jeae142.025 -
Prognostic relevance of mitral and tricuspid regurgitation in patients with severe aortic stenosis
This study investigates the prognostic significance of mitral and tricuspid regurgitation in patients with severe aortic stenosis, revealing that these conditions are associated with higher mortality and influencing treatment strategies.
DOI: 10.1093/ehjci/jey027 -
Continuous spinal anaesthesia with minimally invasive haemodynamic monitoring for surgical hip repair in two patients with severe aortic stenosis
This study reports the successful use of continuous spinal anaesthesia with minimally invasive haemodynamic monitoring in two patients with severe aortic stenosis undergoing surgical hip repair, highlighting the importance of tailored anaesthetic management in high-risk patients.
DOI: 10.1016/j.bjane.2013.03.010 -
Predicting changes in flow category in patients with severe aortic stenosis and preserved left ventricular ejection fraction on medical therapy
A retrospective study of 203 adults with isolated severe aortic stenosis and preserved left ventricular ejection fraction, examining how serial echocardiographic flow categories (normal vs. low flow) switch over time and identifying echocardiographic predictors (notably valvuloa…
DOI: 10.1111/echo.13676 -
The Adverse Impact of Diabetes Mellitus on Left Ventricular Remodeling and Function in Patients With Severe Aortic Stenosis
This study investigates the adverse effects of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis, revealing that diabetes is associated with increased left ventricular mass and reduced systolic function independent of other fac…
DOI: 10.1161/circheartfailure.110.960039 -
Prognostic Significance of ST-Segment Elevation in Leads V<sub>1–2</sub> in Patients With Severe Aortic Stenosis
This study investigates the prognostic significance of ST-segment elevation in leads V1-2 among patients with severe aortic stenosis, revealing that such elevation is associated with higher risks of adverse clinical outcomes including death and the need for surgical aortic valve…
DOI: 10.1253/circj.cj-15-0641 -
Argument for a Doppler echocardiography during exercise in assessing asymptomatic patients with severe aortic stenosis
This prospective study investigates the correlation between exercise stress testing results and hemodynamic measurements obtained through Doppler echocardiography in asymptomatic patients with severe aortic stenosis, revealing significant differences in cardiac output and effect…
DOI: 10.1093/ejechocard/jen163 -
Severe aortic stenosis in elderly patients.
This study investigates the clinical and non-invasive findings in 91 elderly patients with suspected severe aortic stenosis, revealing significant correlations between symptoms, echocardiographic findings, and catheterization data.
DOI: 10.1136/hrt.55.5.480